Glenview Trust Co Purchases Shares of 121,885 Edwards Lifesciences Corporation $EW

Glenview Trust Co purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 121,885 shares of the medical research company’s stock, valued at approximately $11,026,000.

Other large investors have also added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter valued at $25,000. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $89.97 on Friday. The company has a 50 day moving average price of $89.48 and a 200-day moving average price of $84.99. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a market capitalization of $51.81 billion, a PE ratio of 51.71, a P/E/G ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on EW. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target for the company. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,857 shares of company stock valued at $170,305. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.